# Evaluation of Dapagliflozin Taken Twice-daily

> **NCT01217892** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 400 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** dapagliflozin
- **DRUG:** dapagliflozin
- **DRUG:** dapagliflozin
- **DRUG:** metformin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01217892
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2014-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01217892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01217892, "Evaluation of Dapagliflozin Taken Twice-daily". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01217892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*